Success Metrics

Clinical Success Rate
79.4%

Based on 50 completed trials

Completion Rate
79%(50/63)
Active Trials
6(8%)
Results Posted
56%(28 trials)
Terminated
13(17%)

Phase Distribution

Ph not_applicable
1
1%
Ph phase_3
4
5%
Ph early_phase_1
1
1%
Ph phase_1
43
57%
Ph phase_2
25
33%

Phase Distribution

44

Early Stage

25

Mid Stage

4

Late Stage

Phase Distribution74 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
43(58.1%)
Phase 2Efficacy & side effects
25(33.8%)
Phase 3Large-scale testing
4(5.4%)
N/ANon-phased studies
1(1.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

73.5%

50 of 68 finished

Non-Completion Rate

26.5%

18 ended early

Currently Active

6

trials recruiting

Total Trials

75

all time

Status Distribution
Active(6)
Completed(50)
Terminated(18)
Other(1)

Detailed Status

Completed50
Terminated13
Withdrawn5
Active, not recruiting4
Recruiting2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
75
Active
6
Success Rate
79.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.4%)
Phase 143 (58.1%)
Phase 225 (33.8%)
Phase 34 (5.4%)
N/A1 (1.4%)

Trials by Status

active_not_recruiting45%
recruiting23%
suspended11%
terminated1317%
withdrawn57%
completed5067%

Recent Activity

6 active trials
Showing 5 of 75
terminatedphase_1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700
completedphase_1

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

NCT02783625
completedphase_3

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

NCT03593018
completedphase_1

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

NCT01846390
suspendedphase_1

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT06963346
View all 75 trials

Clinical Trials (75)

Showing 20 of 75 trialsScroll for more
NCT03547700Phase 1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Terminated
NCT02783625Phase 1

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Completed
NCT03593018Phase 3

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Completed
NCT01846390Phase 1

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Completed
NCT06963346Phase 1

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Suspended
NCT04447027Phase 1

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Completed
NCT04747236Phase 2

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
NCT03278782Phase 1

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Active Not Recruiting
NCT02512172Phase 1

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Completed
NCT02393794Phase 1

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Active Not Recruiting
NCT04257448Phase 1

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Completed
NCT02512497Phase 1

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Completed
NCT03432741Phase 1

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated
NCT01938833Phase 1

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Terminated
NCT03041012Phase 2

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Completed
NCT02616965Phase 1

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Completed
NCT01638533Phase 1

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Completed
NCT04774068Phase 1

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Completed
NCT01755975Phase 1

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Completed
NCT03703375Phase 3

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
75